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Background: The BRAFV600E mutation, which accounts for about 60–80% papillary thyroid carcinoma(PTC), has
been identifiedas a prognostic marker for risk stratification of PTC patients. However, the BRAFV600E mutation as a
prognostic marker in papillary thyroid microcarcinoma (PTMC) is unclear.
Methods: We performed a retrospective review of 101 patients who underwent surgery for PTMC. We studied the
prevalence of the BRAFV600E mutation. The associations between the BRAFV600E mutation and clinicopathologic
characteristics were analyzed.
Results: The BRAFV600E mutation was observed in 72 patients (71.3%). There was no statistically significant
correlation in age, gender, multifocality, extrathyroidal extension, presence of Hashimoto thyroiditis, and lymph
node metastasis between the BRAFV600E mutant group and wild group.
Conclusions: The BRAFV600E mutation is not significantly associated with prognostic factors in PTMC.
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Thyroid carcinoma is the most common endocrine malig-
nancy and its prevalence is increasing. Recent extensive
use of thyroid ultrasound has led to the increased detec-
tion of non-palpable thyroid nodules. Papillary thyroid
carcinoma (PTC) is the most common type of endocrine
malignancy followed by follicular thyroid carcinoma. The
prevalence of PTC is rapidly increasing and currently
accounts for >95% of all thyroid carcinomas in Korea [1].
Papillary thyroid microcarcinoma (PTMC), a form of
PTC, is defined by the World Health Organization as a
tumor measuring 1 cm or less in its greatest dimension.
Based on the high incidence of PTMC in autopsy studies,
its prognosis is generally favorable and sometimes it is
truly indolent and non-progressive [2]. However, it has
been reported that PTMC may have a metastatic potential* Correspondence: santa@dau.ac.kr
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stated.similar to that of their clinically detectable counterparts
[3-5]. Thus, estimate of prognosis as well as detection of
PTMC has become an important issue.
The BRAFV600E mutation, which accounts for about
60–80% of PTCs, has been identifiedas a promising
prognostic marker for risk stratification of PTC pa-
tients in Korea [4]. However, uncertainties still exist
due to the discordance of studies. Some studies show a
significant relationship between the BRAFV600E mutation
and the high-risk clinicopathologic characteristics of PTC
[4,6]. However, other studies have failed to find a significant
association between the BRAFV600E mutation and high-
risk clinicopathologic characteristics [5,7]. With regards
to PTMC, studies show no significant correlation [7].
Nevertheless, considering its nature, further study of the
characteristics of PTMC through BRAFV600E mutational
status analysis is needed. We investigated the prevalence
of the BRAFV600E mutation andanalyzed the relationship
between the BRAFV600E mutation and clinicopathologic
factors in PTMC.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Patients
The study included review of 253 patients who had under-
gone thyroid cancer surgery between June 2011 and July
2012 at the department of Otolaryngology-Head and Neck
surgery, Dong-A Medical Center, Busan, Korea. Most
patients underwent total thyroidectomy with general
anesthesia. In case of unifocal intrathyroidal microcarci-
noma with no evidence of cervical lymph node metastasis
in preoperative ultrasonography, we conducted thyroid
lobectomy. Central compartment neck dissection was
performed when an enlarged lymph node or invasion of
the thyroid capsule was detected during surgery. Modi-
fied radical neck dissection was conducted in cases of
lateral lymph node metastasis. Of these 253 patients,101
patients diagnosed withconventional PTMC were enrolled
in the study. Informed consent for the evaluation of
BRAFV600E mutation was obtained from all PTMC patients.
We studied the prevalence of the BRAFV600E mutation and
evaluated its correlations with diverse clinicopathologic
features of PTMC.
DNA extraction and the BRAFV600E mutation analysis
We performed the BRAFV600E mutation analysis on paraffin
embedded sections of primary tumors obtained after
thyroidectomy. Genomic DNA was extracted from 10 μm-
thick sections of 10% neutral formalin-fixed paraffin-
embedded tumor tissue blocks using the High Pure PCR
Template Preparation Kit (Roche Applied Science,
Germany). The concentration and purity of the extracted
DNA were determined by a NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies, USA). The extracted
DNA was stocked at −20°C until further use.
The assays for the detection of the BRAFV600E mutation
wereperformed usingthe PNAClampTMBRAF Mutation
Detection kit (Panagene, Inc.,Daejeon, Korea). All reac-
tions were done in 20-μLvolumes using template DNA,
primer and peptide nucleic acid(PNA) probe set, and PCR
master mix. All needed reagents were included with the
kit. Real-time PCR reaction of PNA-mediated clamping
PCR was performed using a CFX 96 (Bio-Rad, USA). PCR
cycling conditions were a 5 min hold at 94°C followed by
40 cycles of 94°C for 30 sec, 70°C for 20 sec, 63°C for
30 sec, and 72°C for 30 sec. In this assay, PNA probes
and DNA primers are used together in the clamping
reaction. Positive signals are detected by intercalation of
fluorescent dye. The PNA probe sequence is comple-
mentary to wild-type DNA to suppress amplification of
wild-type target, thereby enhancing preferential amplifica-
tion of mutant sequences by competitively inhibiting
DNA primer binding to wild-type DNA. PCR efficiency
was determined by measuring the threshold cycle (Ct)
value. Ct values for the control and mutation assays were
obtained by observing the amplification plots. The deltaCt (ΔCt) value was calculated as follows, ensuring that
the sample and Standard Ct values werefrom the tested
sample and clamping control sample: [Standard Ct]-
[Sample Ct] = ΔCt. The cut-off ΔCt was defined as 2.0
for the BRAFV600E mutation (Figure 1).
Statistical analysis
To evaluate the association between BRAFV600E mutation
and prognostic variables, we used χ2or Fisher’s exact
test and logistic regression using the SPSS 18.0 program
(SPSS Inc., Chicago, IL, USA). Statistical significance was
defined as P < 0.05.
Results
All included patients had PTMC confirmed on the surgical
specimen. Of 101 patients, BRAFV600E mutation in PTMC
was observed in 72 patients, indicating a prevalence of
71.3%. The number of patients aged ≥45 years were 76
[mutant: 56 (77.8%), wild: 20(69.0%)] and showed no
statistical significance. The female sex was dominant in
PTMC patients (89.1%); however, there was no statis-
tical significance with BRAFV600E mutation. There were
31 patients with multifocality [mutant: 22(30.6%), wild: 9
(31.0%)], 53 patients with extrathyroidal extension [mutant:
37(51.4%), wild: 16(55.2%)], and 22 patients with combined
Hashimoto’s thyroiditis [mutant: 14(19.4%), wild: 8(27.6%)].
These three factors were not significantly related. There
were 48 T1a patients [mutant: 36(50.0%), wild: 12(41.4%)],
52 T3 patients [mutant: 35(48.6%), wild: 17(58.6%)],
and 1 T4a patient [mutant: 1(1.4%), wild: 0(0%)]. There
were 18 patients with nodal metastasis; among these,
11 were N1a [mutant: 8 (11.1%), wild: 3 (10.3%)] and 7
were N1b [mutant: 3 (4.2%), wild: 4 (13.8%)]. The T and N
staging were not significantly related to BRAFv600Emutation
(Table 1). Distant metastasis to the lung was found in one
patient with wild type and it was not significantly relevant
with BRAFv600E.
In summary, as shown in Tables 1 and 2, there were
no statistically significant correlationswith regards to age,
gender, multifocality, extrathyroidal extension, presence of
Hashimoto thyroiditis, and lymph node metastasis between
the BRAFV600E mutant and wild-type groups.
Discussion
PTMC belongs to the low-risk well-differentiated PTC
group of carcinomas, which are probably of little clinical
significance and do not affect patient survival. However,
PTMC may be associated with lymph node metastases
at presentation and/or loco-regional recurrence during
follow-up [8]. Xing et al. investigated the relationship
between BRAFV600E mutation and PTC-related mortality
in 1,849 patients. The overall mortality was 5.3% vs. 1.1%
(mutant vs. wild, P < 0.001). They showed the BRAFV600E
mutation was significantly associated with increased
Figure 1 The assays for the detection of the BRAFV600Emutation. (A) In a patient with left thyroid nodule, the ΔCt-1 was measured as-2.17,
and was identified as wild-type. (B) In another patient with right thyroid nodule, ΔCt-1 was measured as 8.86, and was identified as mutant type.
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their study, it is uncertain that the BRAFV600E mutation is
correlated with poor prognostic factors in PTMC. In the
currentstudy, we investigated the incidence of BRAFV600E
mutation and the clinicopathologic relationship between
mutant and wild-type groupsofPTMC patients.
BRAF mutations are the most common genetic alter-
ations in PTC. Thesemutations activate the RAS/RAF/
mitogen-activated protein kinase pathway and result in
the malignant transformation of cells. The T1779A
point mutation in BRAF exon 15, resulting in a V600E
amino acid substitution, is the most common and rep-
resents more than 90% of all the mutations found in
the BRAF gene [10]. In Korea, the BRAFV600E mutation
has been reported to be present in about 60–80% of
PTC, which is higher than what is reported in other
countries [4-7,10]. In this study, the BRAFV600E mutation
was observed in 72 PTMC patients (71.3%). Guan et al.
reported that the BRAFV600E mutation was found in 69%of PTC cases in high iodine intake areas and 53% in normal
iodine intake areas (P < 0.0001) [11]. The authors think that
Koreans eat iodine-rich diet, which increases the prevalence
of the BRAFV600E mutation in PTC. Further study is needed
to evaluate the association between BRAFV600E mutation
and the iodine-rich diet in the Korean population.
In our study, we did not find a significant relationship
between BRAFV600E mutation and clinicopathologic charac-
teristics such as older age, gender, Hashimoto thyroiditis,
T staging, nodal metastasis, multifocality, extrathyroidal
extension, and distant metastasis. Based on these results,
it seems that the BRAFV600E mutation is not related to the
prognostic factors for PTMC thatdetermine the invasive-
ness of the tumors.
Several studies have shown an association between the
BRAFV600E mutation and prognostic factors in PTC.
Kebebewet al. reported the BRAFV600E mutation was asso-
ciated with older age (P = 0.0381) [6]. However, Kim et al.
[4] and Lee et al. [12] revealed that age was not associated




Mutant (n = 72) Wild (n = 29) χ2 Pvalue
Age 0.862 0.353
<45 years 25(24.8) 16(22.2) 9(31.0)
≥45 years 76(75.2) 56(77.8) 20(69.0)
Gender 0.669 0.413
Female 90(89.1) 63(87.5) 27(93.1)
Male 11(10.9) 9(12.5) 2(6.9)
Multifocality 0.002 0.962
No 70(69.3) 50(69.4) 20(69.0)
Yes 31(30.7) 22(30.6) 9(31.0)
Extrathyroidal extension 0.119 0.73
No 48(47.5) 35(48.6) 13(44.8)
Yes 53(52.5) 37(51.4) 16(55.2)
Hashimoto thyroiditis 0.804 0.37
Not combined 79(78.2) 58(80.6) 21(72.4)
Combined 22(21.8) 14(19.4) 8(27.6)
T staging 1.128 0.569
T1a 48(47.5) 36(50.0) 12(41.4)
T3 52(51.5) 35(48.6) 17(58.6)
T4a 1(1.0) 1(1.4) 0(0)
Nodal metastasis 2.973 0.226
N0 83(82.2) 61(84.7) 22(75.9)
N1a 11(10.9) 8(11.1) 3(10.3)
N1b 7(6.9) 3(4.2) 4(13.8)
Distant metastasis 2.508 0.113
No 100(99.0) 72(100.0) 28(96.6)
Yes 1(1.0) 0(0.0) 1(3.4)
Table 2 Summary of logistic regression for variables predicting the BRAFV600Emutation in PTMC
Variables B SE Wald Df P value Odds ratio 95% confidence interval
Low High
Age (1 = <45, 0 =≥45*) −0.541 0.535 1.024 1 0.312 0.582 0.204 1.661
Gender (1 = female, 0 =male*) −0.673 0.854 0.621 1 0.431 0.510 0.096 2.720
Multifocality (1 = no, 0 = yes*) −0.007 0.512 0.000 1 0.989 0.993 0.364 2.707
Extrathyroidal extension (1 = no, 0 = yes*) 0.101 0.485 0.044 1 0.835 1.106 0.428 2.860
Hashimoto thyroiditis (1 = not combined, 0 = combined*) 0.481 0.532 0.817 1 0.366 1.617 0.570 4.586
Nodal metastasis (Ib) - - 2.636 2 0.268 - - -
Nodal metastasis (1 = N0, 0 = NIb*) 1.384 .855 2.622 1 0.105 3.992 0.747 21.325
Nodal metastasis (1 = NIa, 0 = NIb*) 1.303 1.053 1.530 1 0.216 3.680 0.467 29.005
Constant −0.015 1.230 0.000 1 0.991 0.986 - -
*Reference group.
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of mutation in patients aged ≥ 45 years was higher than in
wild-type patients (77.8% vs. 69%, P = 0.353). However,
there was no significant association in patients with old age.
Kim et al. [4] and Xu et al. [13] showed the BRAFV600E mu-
tation was associated with male gender. We found a higher-
prevalence of mutation in the male gender (12.5% vs. 6.9%,
P = 0.413), althoughthis is not statistically significant due to
the small number of male patients. Further, other reports
showed no association between the BRAFV600E muta-
tion and male gender [5-7,12]. Lim et al. reported that
the BRAFV600E mutation was associated with extrathyroidal
extension and multifocality [14]. Kim et al. showed no
significant relationship between the BRAFV600E mutation
and extrathyroidal extension and multifocality [7]. Our re-
sults also showed no relationships (P >0.05). However, in
the study by Park et al., multifocality was associated with
the BRAFV600E mutation [12]. Lim et al. reported a signifi-
cant association between the BRAFV600E mutation and
Hashimoto thyroiditis [14]. In this study, we could not find
these significant associations. Several studies have reported
that lymph node metastasis was significantly higher in pa-
tients withthe BRAFV600E mutation [4,6,12,14]. In our re-
sult, lymph node metastasis had no significant association
with the BRAFV600E mutation (15.3% vs. 24.1%, P = 0.226).
Ahn et al. [5] and Kim et al. [7] also found that the lymph
node metastasis did not differ significantly between pa-
tients with and without the BRAFV600E mutation.
Against expectations, nodal metastasis and distant metas-
tasis showed a slight negative association with BRAFv600E
mutation. This result seems to be due to the small sample
size andshort follow-up period time. Therefore, oncologic
outcomes such as recurrence, metastasis, and survival rate
could not be observed. Further, the higher incidence of
BRAFV600E mutation in Korea may have had an effect on
the study results. Future studies with larger patient groups
are needed to evaluate the oncologic outcomes.Conclusions
In this study, we have shown that the prevalence of the
BRAFV600E mutation was 71.3% in 101 PTMC patients in
Korea. The BRAFV600E mutation was not associated with
prognostic factors in patients with PTMC.Consent
Our study is retrospective study, and all of our patients
agreed to us using their medical information.
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